Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107034 | 0.86 | NPBWR1 (0.58) | NPBWR1DGAT1KCNH2DYRK1ADYRK1B | |
| SCHEMBL18931745 | 0.82 | SCN10A (0.45) | KIF11METAP2KCNH2CHUKDYRK1A | |
| SCHEMBL5681855 | 0.80 | NPSR1 (0.59) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL8710496 | 0.79 | SCN10A (0.33) | KIF11KCNH2SCN10A | |
| SCHEMBL2711960 | 0.79 | KDM4E (0.50) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL5679579 | 0.79 | MAPT (0.57) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL666767 | 0.79 | NPBWR1 (0.43) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL2360716 | 0.79 | MASP2 (0.48) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL21496795 | 0.79 | NPBWR1 (0.43) | NPBWR1KIF11KDM4EMETAP2DGAT1 | |
| SCHEMBL18628731 | 0.79 | NPBWR1 (0.43) | NPBWR1KIF11KDM4EMETAP2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5106863-A | Antiulcer agents, gastrointestinal disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-04-21 | — | — | US | claimed |
| JP-63150286-A | — | — | None | — | — | JP | disclosed |
| US-8163768-B2 | 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus | AVENTIS PHARMA S.A.. (FR) | 2012-04-24 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-1910366-B1 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-1746097-B1 | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | AVENTIS PHARMA SA (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-4721718-A | 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers | G. D. SEARLE & CO. (US) | 1988-01-26 | — | — | US | disclosed |
| EP-0232399-A1 | NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1987-08-19 | — | — | EP | disclosed |
| US-4687775-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1987-08-18 | — | — | US | disclosed |
| EP-0214479-A2 | Benzimidazol-2-ylpyridinium compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-03-18 | — | — | EP | disclosed |
| WO-1987001114-A2 | NEW AMINES, PROCESS FOR THEIR MANUFACTURE, THEIR USE AND MEDICINES CONTAINING THEM | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-02-26 | — | — | WO | disclosed |
| CN-86104636-A | Produce the method for pyridine derivate | — | 1987-01-28 | — | — | CN | disclosed |
| EP-0208452-A2 | Pyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-01-14 | — | — | EP | disclosed |
| EP-0204215-A1 | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines | G.D. Searle & Co. (US) | 1986-12-10 | — | — | EP | disclosed |
| US-4472409-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-09-18 | — | — | US | disclosed |
| EP-0080602-A1 | Substituted benzimidazoles, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-06-08 | — | — | EP | disclosed |